Another 18-week, randomized, open-label study was conducted to understand the effect of basal bolus (BB) vs. basal-only insulin regimen on glycemic control in 236 patients with inadequately controlled T2DM on basal insulin and oral antidiabetic drugs (OADs). This evidence concerns the gene INS and type 2 diabetes mellitus.